emerging-tech-investing Sona Nanotech Reports 80% Response Rate in First-In-Human THT Cancer Therapy Study
emerging-tech-investing Sona Nanotech's Targeted Hyperthermia Therapy To Be Presented at the International 19th Canadian Melanoma Conference
Sona Nanotech's THT Cancer Therapy Preclinical Efficacy Studies Published In Peer-Reviewed Scientific Journal
emerging-tech-investing Sona Nanotech's THT Cancer Studies Demonstrates Strong Efficacy in Third Preclinical Study and Plans for First-in-human Early Feasibility Study
Sona Nanotech to Showcase Its THT Cancer Therapy at NCL 20th Anniversary Symposium and Provides Corporate Update
Sona Nanotech Closes Private Placement Financing to Raise $1,500,000 in Gross Proceeds and Announces Additional Financing
Sona's Cancer Therapy Triggers Abscopal Effect, Eliminating Distant Tumors In Preclinical Melanoma Study
Acquisition of “Thompson Falls” High-Grade Antimony Project Adjacent to America’s only Antimony Smelter
Valeura Energy: Positioned for Organic Growth and Accretive M&A in Southeast Asia’s Offshore Oil Sector
